Dr. Keer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Summary
- Oncologist leading R& D efforts at Taiho Oncology, Inc. as Chief Medical Officer
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1997
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1993
Northwestern University The Feinberg School of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 2002 - 2026
Clinical Trials
- Guadecitabine Extension Study Start of enrollment: 2018 Jul 18
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) Start of enrollment: 2019 Sep 30
Publications & Presentations
PubMed
- A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan
Future Oncology. 2025-04-01 - Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.Alex Bataller, Koji Sasaki, Samuel Urrutia, Guillermo Montalban-Bravo, Alexandre Bazinet
Blood Cancer Journal. 2025-03-31 - 2 citationsOral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.Klaus Geissler, Zdenek Koristek, Teresa Bernal Del Castillo, Jan Novák, Gabriela Rodríguez-Macías
British Journal of Haematology. 2024-11-01
Press Mentions
Taiho Oncology Presents Real-World Findings for LONSURF® at the ASCO Gastrointestinal Cancers SymposiumJanuary 25th, 2025- Taiho Oncology Data at ASH Annual Meeting Highlight Progress in Oral Therapies for Patients with Blood CancersDecember 9th, 2024
- Astex Announces That the Phase 3 ASCERTAIN - Acute Myeloid Leukemia (AML) Clinical Study of Oral Hypomethylating Agent Decitabine and Cedazuridine Fixed-Dose Combination (ASTX727 or DEC-C) Met the Trial’s Primary EndpointMay 12th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
